Literature DB >> 29477403

Reliability, Validity, and Responsiveness of InFLUenza Patient-Reported Outcome (FLU-PRO©) Scores in Influenza-Positive Patients.

John H Powers1, Elizabeth D Bacci2, M Lourdes Guerrero3, Nancy Kline Leidy4, Sonja Stringer4, Katherine Kim4, Matthew J Memoli5, Alison Han5, Mary P Fairchok6, Wei-Ju Chen7, John C Arnold8, Patrick J Danaher9, Tahaniyat Lalani10, Michelande Ridoré11, Timothy H Burgess12, Eugene V Millar7, Andrés Hernández13, Patricia Rodríguez-Zulueta14, Mary C Smolskis4, Hilda Ortega-Gallegos3, Sarah Pett15, William Fischer16, Daniel Gillor17, Laura Moreno Macias18, Anna DuVal19, Richard Rothman19, Andrea Dugas19, Guillermo M Ruiz-Palacios3.   

Abstract

OBJECTIVES: To assess the reliability, validity, and responsiveness of InFLUenza Patient-Reported Outcome (FLU-PRO©) scores for quantifying the presence and severity of influenza symptoms.
METHODS: An observational prospective cohort study of adults (≥18 years) with influenza-like illness in the United States, the United Kingdom, Mexico, and South America was conducted. Participants completed the 37-item draft FLU-PRO daily for up to 14 days. Item-level and factor analyses were used to remove items and determine factor structure. Reliability of the final tool was estimated using Cronbach α and intraclass correlation coefficients (2-day reliability). Convergent and known-groups validity and responsiveness were assessed using global assessments of influenza severity and return to usual health.
RESULTS: Of the 536 patients enrolled, 221 influenza-positive subjects comprised the analytical sample. The mean age of the patients was 40.7 years, 60.2% were women, and 59.7% were white. The final 32-item measure has six factors/domains (nose, throat, eyes, chest/respiratory, gastrointestinal, and body/systemic), with a higher order factor representing symptom severity overall (comparative fit index = 0.92; root mean square error of approximation = 0.06). Cronbach α was high (total = 0.92; domain range = 0.71-0.87); test-retest reliability (intraclass correlation coefficient, day 1-day 2) was 0.83 for total scores and 0.57 to 0.79 for domains. Day 1 FLU-PRO domain and total scores were moderately to highly correlated (≥0.30) with Patient Global Rating of Flu Severity (except nose and throat). Consistent with known-groups validity, scores differentiated severity groups on the basis of global rating (total: F = 57.2, P < 0.001; domains: F = 8.9-67.5, P < 0.001). Subjects reporting return to usual health showed significantly greater (P < 0.05) FLU-PRO score improvement by day 7 than did those who did not, suggesting score responsiveness.
CONCLUSIONS: Results suggest that FLU-PRO scores are reliable, valid, and responsive to change in influenza-positive adults.
Copyright © 2018 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  influenza; patient-reported outcome; psychometric; reliability; responsiveness; validity

Mesh:

Year:  2017        PMID: 29477403      PMCID: PMC5831548          DOI: 10.1016/j.jval.2017.04.014

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  12 in total

1.  Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1--eliciting concepts for a new PRO instrument.

Authors:  Donald L Patrick; Laurie B Burke; Chad J Gwaltney; Nancy Kline Leidy; Mona L Martin; Elizabeth Molsen; Lena Ring
Journal:  Value Health       Date:  2011-10-13       Impact factor: 5.725

2.  Development and validation of the Influenza Intensity and Impact Questionnaire (FluiiQ™).

Authors:  Richard H Osborne; Josephine M Norquist; Gerald R Elsworth; Lucy Busija; Vinay Mehta; Tim Herring; Swati B Gupta
Journal:  Value Health       Date:  2011-05-08       Impact factor: 5.725

3.  FDA draft guidance and health-outcomes research.

Authors:  Dennis A Revicki
Journal:  Lancet       Date:  2007-02-17       Impact factor: 79.321

4.  What is sufficient evidence for the reliability and validity of patient-reported outcome measures?

Authors:  Marlene H Frost; Bryce B Reeve; Astra M Liepa; Joseph W Stauffer; Ron D Hays
Journal:  Value Health       Date:  2007 Nov-Dec       Impact factor: 5.725

5.  Does Influenza Vaccination Modify Influenza Severity? Data on Older Adults Hospitalized With Influenza During the 2012-2013 Season in the United States.

Authors:  Carmen S Arriola; Evan J Anderson; Joan Baumbach; Nancy Bennett; Susan Bohm; Mary Hill; Mary Lou Lindegren; Krista Lung; James Meek; Elizabeth Mermel; Lisa Miller; Maya L Monroe; Craig Morin; Oluwakemi Oni; Arthur Reingold; William Schaffner; Ann Thomas; Shelley M Zansky; Lyn Finelli; Sandra S Chaves
Journal:  J Infect Dis       Date:  2015-03-27       Impact factor: 5.226

6.  Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation.

Authors:  Diane Wild; Alyson Grove; Mona Martin; Sonya Eremenco; Sandra McElroy; Aneesa Verjee-Lorenz; Pennifer Erikson
Journal:  Value Health       Date:  2005 Mar-Apr       Impact factor: 5.725

Review 7.  Use of existing patient-reported outcome (PRO) instruments and their modification: the ISPOR Good Research Practices for Evaluating and Documenting Content Validity for the Use of Existing Instruments and Their Modification PRO Task Force Report.

Authors:  Margaret Rothman; Laurie Burke; Pennifer Erickson; Nancy Kline Leidy; Donald L Patrick; Charles D Petrie
Journal:  Value Health       Date:  2009-09-25       Impact factor: 5.725

8.  Development of the Flu-PRO: a patient-reported outcome (PRO) instrument to evaluate symptoms of influenza.

Authors:  John H Powers; M Lourdes Guerrero; Nancy Kline Leidy; Mary P Fairchok; Alice Rosenberg; Andrés Hernández; Sonja Stringer; Christina Schofield; Patricia Rodríguez-Zulueta; Katherine Kim; Patrick J Danaher; Hilda Ortega-Gallegos; Elizabeth Dansie Bacci; Nathaniel Stepp; Arturo Galindo-Fraga; Kristina St Clair; Michael Rajnik; Erin A McDonough; Michelande Ridoré; John C Arnold; Eugene V Millar; Guillermo M Ruiz-Palacios
Journal:  BMC Infect Dis       Date:  2016-01-05       Impact factor: 3.090

9.  Factors associated with hospitalization for seasonal influenza in a Japanese nonelderly cohort.

Authors:  Sachiko Ono; Yosuke Ono; Hiroki Matsui; Hideo Yasunaga
Journal:  BMC Public Health       Date:  2016-09-02       Impact factor: 3.295

10.  Influenza symptoms and their impact on elderly adults: randomised trial of AS03-adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccines.

Authors:  Gerrit A van Essen; Jiri Beran; Jeanne-Marie Devaster; Christelle Durand; Xavier Duval; Meral Esen; Ann R Falsey; Gregory Feldman; Pierre Gervais; Bruce L Innis; Martina Kovac; Odile Launay; Geert Leroux-Roels; Janet E McElhaney; Shelly McNeil; Mohammed Oujaa; Jan Hendrik Richardus; Guillermo Ruiz-Palacios; Richard H Osborne; Lidia Oostvogels
Journal:  Influenza Other Respir Viruses       Date:  2014-04-04       Impact factor: 4.380

View more
  12 in total

Review 1.  Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference.

Authors:  John H Beigel; Hannah H Nam; Peter L Adams; Amy Krafft; William L Ince; Samer S El-Kamary; Amy C Sims
Journal:  Antiviral Res       Date:  2019-04-08       Impact factor: 5.970

2.  A Dose-finding Study of a Wild-type Influenza A(H3N2) Virus in a Healthy Volunteer Human Challenge Model.

Authors:  Alison Han; Lindsay M Czajkowski; Amanda Donaldson; Holly Ann Baus; Susan M Reed; Rani S Athota; Tyler Bristol; Luz Angela Rosas; Adriana Cervantes-Medina; Jeffery K Taubenberger; Matthew J Memoli
Journal:  Clin Infect Dis       Date:  2019-11-27       Impact factor: 9.079

3.  Performance of the inFLUenza Patient-Reported Outcome Plus (FLU-PRO Plus) Instrument in Patients With Coronavirus Disease 2019.

Authors:  Stephanie A Richard; Nusrat J Epsi; Simon Pollett; David A Lindholm; Allison M W Malloy; Ryan Maves; Gregory C Utz; Tahaniyat Lalani; Alfred G Smith; Rupal M Mody; Anuradha Ganesan; Rhonda E Colombo; Christopher J Colombo; Sharon W Chi; Nikhil Huprikar; Derek T Larson; Samantha Bazan; Cristian Madar; Charlotte Lanteri; Julia S Rozman; Caroline English; Katrin Mende; David R Tribble; Brian K Agan; Timothy H Burgess; John H Powers
Journal:  Open Forum Infect Dis       Date:  2021-10-08       Impact factor: 3.835

4.  Using the Influenza Patient-reported Outcome (FLU-PRO) diary to evaluate symptoms of influenza viral infection in a healthy human challenge model.

Authors:  Alison Han; Jiat-Ling Poon; John H Powers; Nancy K Leidy; Ren Yu; Matthew J Memoli
Journal:  BMC Infect Dis       Date:  2018-07-28       Impact factor: 3.090

5.  Comparison of Rates of Hospitalization Between Single and Dual Virus Detection in a Mexican Cohort of Children and Adults With Influenza-Like Illness.

Authors:  Daniel E Noyola; Sally Hunsberger; Raydel Valdés Salgado; John H Powers; Arturo Galindo-Fraga; Ana A Ortiz-Hernández; Alejandra Ramirez-Venegas; Sarbelio Moreno-Espinosa; Beatriz Llamosas-Gallardo; M Lourdes Guerrero; John H Beigel; Guillermo Ruiz-Palacios; Santiago Perez-Patrigeon
Journal:  Open Forum Infect Dis       Date:  2019-10-03       Impact factor: 3.835

6.  Acute Symptoms of Mild to Moderate COVID-19 Are Highly Heterogeneous Across Individuals and Over Time.

Authors:  Thomas L Rodebaugh; Madelyn R Frumkin; Angela M Reiersen; Eric J Lenze; Michael S Avidan; J Philip Miller; Jay F Piccirillo; Charles F Zorumski; Caline Mattar
Journal:  Open Forum Infect Dis       Date:  2021-03-01       Impact factor: 3.835

7.  Testing and Psychometric Validation of a Pediatric Instrument to Self-Assess Symptoms of the Common Cold.

Authors:  Rob Arbuckle; Patricia Halstead; Chris Marshall; Brenda Zimmerman; Kate Bolton; Antoine Regnault; Cathy Gelotte
Journal:  Patient       Date:  2020-11-11       Impact factor: 3.883

8.  Impact of respiratory syncytial virus disease on quality of life in adults aged ≥50 years: A qualitative patient experience cross-sectional study.

Authors:  Desmond Curran; Eliazar Sabater Cabrera; Benjamin Bracke; Kimberly Raymond; April Foster; Cindy Umanzor; Philibert Goulet; John H Powers
Journal:  Influenza Other Respir Viruses       Date:  2022-01-03       Impact factor: 4.380

9.  Efficacy of FLU-v, a broad-spectrum influenza vaccine, in a randomized phase IIb human influenza challenge study.

Authors:  Olga Pleguezuelos; Emma James; Ana Fernandez; Victor Lopes; Luz Angela Rosas; Adriana Cervantes-Medina; Jason Cleath; Kristina Edwards; Dana Neitzey; Wenjuan Gu; Sally Hunsberger; Jeffery K Taubenberger; Gregory Stoloff; Matthew J Memoli
Journal:  NPJ Vaccines       Date:  2020-03-13       Impact factor: 7.344

10.  The Clinical Course of COVID-19 in the Outpatient Setting: A Prospective Cohort Study.

Authors:  Paul W Blair; Diane M Brown; Minyoung Jang; Annukka A R Antar; Jeanne C Keruly; Vismaya S Bachu; Jennifer L Townsend; Jeffrey A Tornheim; Sara C Keller; Lauren Sauer; David L Thomas; Yukari C Manabe
Journal:  Open Forum Infect Dis       Date:  2021-01-05       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.